scispace - formally typeset
Open AccessJournal ArticleDOI

The Major Neutralizing Antibody Responses to Recombinant Anthrax Lethal and Edema Factors Are Directed to Non-Cross-Reactive Epitopes

TLDR
The identification of linear B-cell epitopes of EF increases understanding of the immunogenicity of EF and LF and offers perspective for the development of new strategies for vaccination against anthrax.
Abstract
Anthrax lethal and edema toxins (LeTx and EdTx, respectively) form by binding of lethal factor (LF) or edema factor (EF) to the pore-forming moiety protective antigen (PA). Immunity to LF and EF protects animals from anthrax spore challenge and neutralizes anthrax toxins. The goal of the present study is to identify linear B-cell epitopes of EF and to determine the relative contributions of cross-reactive antibodies of EF and LF to LeTx and EdTx neutralization. A/J mice were immunized with recombinant LF (rLF) or rEF. Pools of LF or EF immune sera were tested for reactivity to rLF or rEF by enzyme-linked immunosorbent assays, in vitro neutralization of LeTx and EdTx, and binding to solid-phase LF and EF decapeptides. Cross-reactive antibodies were isolated by column absorption of EF-binding antibodies from LF immune sera and by column absorption of LF-binding antibodies from EF immune sera. The resulting fractions were subjected to the same assays. Major cross-reactive epitopes were identified as EF amino acids (aa) 257 to 268 and LF aa 265 to 274. Whole LF and EF immune sera neutralized LeTx and EdTx, respectively. However, LF sera did not neutralize EdTx, nor did EF sera neutralize LeTx. Purified cross-reactive immunoglobulin G also failed to cross-neutralize. Cross-reactive B-cell epitopes in the PA-binding domains of whole rLF and rEF occur and have been identified; however, the major anthrax toxin-neutralizing humoral responses to these antigens are constituted by non-cross-reactive epitopes. This work increases understanding of the immunogenicity of EF and LF and offers perspective for the development of new strategies for vaccination against anthrax.

read more

Citations
More filters
Book ChapterDOI

Immunity to Ricin: Fundamental Insights into Toxin–Antibody Interactions

TL;DR: The characterization of dozens of monoclonal antibodies against the toxin's enzymatic and binding subunits has begun to reveal fundamental insights into the underlying mechanisms by which antibodies neutralize (or fail to neutralize) ricin in systemic and mucosal compartments.
Journal ArticleDOI

Mouse Monoclonal Antibodies to Anthrax Edema Factor Protect against Infection

TL;DR: Evidence is provided of the first direct evidence that monoclonal antibody-mediated neutralization of EF alone is sufficient to delay anthrax disease progression, and the antibody appears to be the first antibody reported to neutralize EF by binding to the catalytic CB domain.

Mouse monoclonal antibodies to anthrax edema factor protect against

TL;DR: In this article, anti-EF monoclonal antibodies (MAb) were produced following immunization of mice, and four of the antibodies were fully characterized; they were able to detect purified edema factor in Western blot analysis.
Journal ArticleDOI

Vaccines against anthrax based on recombinant protective antigen: problems and solutions.

TL;DR: This review is devoted to challenges and achievements in the design of vaccines based on the anthrax recombinant protective antigen (rPA), with a focus on problems of PA instability that are greatly enhanced when using aluminum adjuvants.
Journal ArticleDOI

Regulation of anthrax toxin-specific antibody titers by natural killer T cell-derived IL-4 and IFNγ.

TL;DR: Data suggest targeted skewing of the Th2 response by α-GC derivatives can be exploited to optimize anthrax vaccination.
References
More filters
Journal ArticleDOI

The Protein Data Bank

TL;DR: The goals of the PDB are described, the systems in place for data deposition and access, how to obtain further information and plans for the future development of the resource are described.
Journal ArticleDOI

Anthrax toxin edema factor: a bacterial adenylate cyclase that increases cyclic AMP concentrations of eukaryotic cells.

TL;DR: It is shown here that EF is an adenylate cyclase [ATP pyrophosphate-lyase (cyclizing), EC 4.6.1] produced by Bacillus anthracis in an inactive form and nearly equals that of the most active known cyclase.
Journal ArticleDOI

Structural basis for the activation of anthrax adenylyl cyclase exotoxin by calmodulin.

TL;DR: Allosteric changes of oedema factor provide the first molecular details of how calmodulin modulates one of its targets.
Journal ArticleDOI

Early events in lupus humoral autoimmunity suggest initiation through molecular mimicry.

TL;DR: The hypothesis that some humoral autoimmunity in human lupus arises through molecular mimicry between EBNA-1 and l upus autoantigens is supported and further evidence to suspect an etiologic role for Epstein-Barr virus in SLE is provided.
Journal ArticleDOI

Cellular and systemic effects of anthrax lethal toxin and edema toxin.

TL;DR: An overview of the current understanding of anthrax toxin effects in animal models and the cytotoxicity induced by LT in different cells and a brief reexamination of early historic findings on toxin in vivo effects is presented.
Related Papers (5)